Press Release: Novartis investigational -2-

References

1. Novartis data on file.

2. Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2

AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan

Research and Ongoing Clinical Trials at the American Society of

Nephrology (ASN) Kidney Week 2022. Chinook Therapeutics, Inc. Accessed

October 18, 2023.

https://investors.chinooktx.com/news-releases/news-release-details/chinook-therapeutics-presents-updated-data-atrasentan-phase-2

3. Kim SG, Akinfolarin AA, Inker LA, et al. WCN23-1117 ATRASENTAN IN

PATIENTS WITH PROTEINURIC GLOMERULAR DISEASES -- THE AFFINITY STUDY.

Kidney Int Rep. 2023;8(9):1902. doi:10.1016/j.ekir.2023.02.1089.

4. Kim SG, Inker LA, Packham DK, et al. WCN23-1126 ATRASENTAN FOR THE

TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS OF THE AFFINITY STUDY.

Kidney Int Rep. 2023;8(9):1902. doi:10.1016/j.ekir.2023.02.1088.

5. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice

Guideline for the Management of Glomerular Diseases. Kidney Int.

2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021.

6. Reich HN, Troyanov SAA, Scholey JW, Cattran DC. Remission of Proteinuria

Improves Prognosis in IgA Nephropathy. J Am Soc Nephrol.

2007;18(12):3177-3183. doi:10.1681/ASN.2007050526.

7. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the

pathogenesis and treatment of IgA nephropathy. Kidney Int.

2012;81(9):833-843. doi:10.1038/ki.2011.501.

8. Xie J, Kiryluk K, Wang W, et al. Predicting Progression of IgA

Nephropathy: New Clinical Progression Risk Score. Moura IC, ed. PLoS ONE.

2012;7(6):e38904. doi:10.1371/journal.pone.0038904.

9. Novartis completes acquisition of Chinook Therapeutics. Novartis.

Accessed October 18,

2023. https://www.novartis.com/news/media-releases/novartis-completes-acq

uisition-chinook-therapeutics

10. Novartis investigational iptacopan Phase III study demonstrates

clinically meaningful and highly statistically significant proteinuria

reduction in patients with IgA nephropathy (IgAN). Novartis. Accessed

October 18,

2023. https://www.novartis.com/news/media-releases/novartis-investigation

al-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highl

y-statistically-significant-proteinuria-reduction-patients-iga-nephropath

y-igan

11. ClinicalTrials.gov. Atrasentan in Patients With IgA Nephropathy (ALIGN).

NCT04573478. Accessed October 18,

2023. https://clinicaltrials.gov/study/NCT04573478

12. Lambers Heerspink H, Jardine M, Kohan DE, et al. WCN23-1085 A PHASE 3,

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN

PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY. Kidney Int Rep.

2023;8(3):S279-S280. doi:10.1016/j.ekir.2023.02.630.

13. McGrogan A, Franssen CFM, de Vries CS. The incidence of primary

glomerulonephritis worldwide: a systematic review of the literature.

Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665.

14. Lerma EV, Bensink ME, Thakker KM, et al. Impact of Proteinuria and Kidney

Function Decline on Health Care Costs and Resource Utilization in Adults

With IgA Nephropathy in the United States: A Retrospective Analysis.

Kidney Med. 2023;5(9). doi:10.1016/j.xkme.2023.100693.

15. U.S. Census Bureau. QuickFacts: United States. Accessed October 26,

2023. https://www.census.gov/quickfacts/fact/table/US/PST045222

16. Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ.

The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial

Transplant. 2023;38(10):2340-2349. doi:10.1093/ndt/gfad082.

17. Lafayette RA, Kelepouris E. Immunoglobulin A Nephropathy: Advances in

Understanding of Pathogenesis and Treatment. Am J Nephrol. 2018;47(Suppl.

1):43-52. doi:10.1159/000481636.

18. Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primer.

2016;2(1):16001. doi:10.1038/nrdp.2016.1.

19. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol.

2017;12(4):677-686. doi:10.2215/CJN.07420716.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269

Zain Iqbal +41 61 324 0390

(END) Dow Jones Newswires

October 30, 2023 02:15 ET (06:15 GMT)